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ABSTRACT
The following review article main objective seeks to provide an approach from a health care first level institution, of one of the most 
frequent queries in pediatrics and general medicine, stunted growth. The relation of consults for short stature in children is higher in boys 
rather than girls, but most of the times girls have more prevalence of organic diseases and growth disturbances than boys.   When we 
receive a patient who complains of short stature, we should ask a series of questions and take some anthropometric measures to classify 
the child and determine the diagnosis. The first level doctor has to understand the meaning of these measures and determine if the child’s 
short stature is whether pathological or physiological. Then the child has to be classified again, if it is a physiological short stature, he 
needs to be group into genetic short stature or constitutional delay of growth and development, which constitutes by far the 80% of the 
cases. MÉD.UIS. 2016;29(3):73-8.
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Talla baja, enfoque de primer nivel y diagnóstico
RESUMEN
El siguiente artículo tiene como objetivo principal dar un enfoque de primer nivel a uno de los motivos de consulta más frecuentes en 
pediatría y medicina general, la talla baja. El número de consultas por talla baja en la infancia es mucho mayor en niños que en niñas, 
pero la mayoría de las veces las niñas presentan mayor prevalencia de patologías orgánicas y desordenes del crecimiento que los niños. 
Cuando recibimos a un paciente que consulta por talla baja debemos hacer una serie de preguntas dirigidas y tomar ciertas medidas 
antropométricas para poder llegar a un diagnóstico correcto. El médico general de primer nivel debe entender el significado de cada una 
de estas medidas y clasificar al niño en talla baja variante normal o patológica. Luego de esto el niño debe volver a ser clasificado, si se 
determinó que era variante normal, en talla baja familiar o retardo constitucional del crecimiento y el desarrollo, que constituyen cerca 
del 80%. MÉD.UIS. 2016;29(3):73-8.
Palabras clave: Trastornos del Crecimiento. Crecimiento y Desarrollo. Estatura por Edad. 
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IntroductIon
Short stature in children is defined as a height 
below two standard deviations (-2SD), or under the 
third percentile for age, gender and appropriate 
population reference from pubertal stage. This 
concept should not be confused with poor growth 
which is defined as a height velocity (cm/year) below 
two standard deviations from the expected velocity 
for that age1.
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Growth is a very complex process in which a number of 
features occur only in human being, and some others 
are common within other species. Fetal growth is the 
fastest in all human growth phases whose highest peak 
occurres in the second trimester. Later in childhood 
growth slows and remains constant until a new peak 
at puberty. Despite the entire hormonal system is 
involved in the process of height gain, the Insul - live 
Growth Factor (IGF) system has one of the lead roles, 
and it is involved in all phases of human growth2,3.
All this process begins in the hypothalamus where 
the Growth Hormone Release Hormone is secreted 
and goes to the adenohypophysis to stimulate the 
secretion of Growth Hormone (GH), which has an 
anabolic role in the entire organism by stimulating 
first the liver, to produce the IGF system; these 
hormones activate receptors in all the tissues, 
producing glycogenolysis, lipolysis, rising mitosis 
rate in epiphyseal growth plate chondrocytes 
which increases bones size4-5. It has been reported 
that alteration in IGF’s mice receptors affects 
normal growing; in IGF-I generated a uterus growth 
restriction that altered postnatal growth, which 
reached the 30% of its final height target. Also it was 
found that abnormal IGF II receptors generated a 
uterus decrease in size of 40% without modifying 
postnatal growth2,3,6.
The following review article’s main objective 
seeks to provide an approach from a health care 
first level institution, of one of the most frequent 
queries in paediatrics and general medicine, stunted 
growth. This is a problem that is frequently seen 
by the patient’s family as something distressing, 
height plays an important role in self-esteem and 
psychosocial development of people, a child who 
feels that is not growing like his friends or family may 
bring mood disorders that prevent a properly social, 
emotional and psychological development7,8.
EpIdEmIology
The relationship of visit to pediatricians or general 
doctors for stunting in boys versus girls is 1.9:1 
being greater the number of visits in boys, however 
the major growth disturbances occur in girls, who 
present a higher prevalence of organic pathologies 
(40%). This allows us to conclude that short stature 
is being underdiagnosed in girls, most probably 
because social pressure has imposed that male 
should be taller than female, therefore short stature 
in boys result more concerning9.
A population-based survey of growth made on 
Utah, assessed height and growth speed in nearly 
115 000 American children; they found 555 infants 
with short stature and poor growth rate, but only 
5% had an endocrine disorder9. That is a data from 
a developed country, but short stature is presented 
very differently on underdeveloped countries, 
because there is a higher prevalence of malnutrition 
and other organic causes which are more common 
than endocrine etiologies.
A retrospective observational study performed in 
Mexico among 341 children who had been referred to 
the endocrinologist because of short stature, found 
out that 45% of the cases had a pathologic etiology, 
46% were physiological variants and 9% indicated a 
normal growth. Also concludes that the average of 
age at consult was 10 years, and 26% of the patients 
already were over 12 years and have reached the 
maximum peak of height velocity10.
A retrospective and descriptive study in Guadalajara 
(Spain), with children in paediatric consult in the 
endocrine service, shows that 30.2% of the consult 
was because of short stature. Majority, 25.5% of 
these were attributed to Constitutional Delayed of 
Growth (CDG), 21.4% to Genetic Short Stature (GST) 
and only 4% to growth hormone deficiency. The 14.5% 
of the patients were treated with growth hormone. 
Average age of diagnosis of short stature was 7.3 
years, similar in boys and girls11.
matErIals and mEthods
We searched and selected articles from PubMed, 
SciELo, EBSCO HOST, ScienceDirect and UpToDate 
by using “short stature”, “stature by age”, “growth 
disorders”, “growth hormone deficiencies”, “bone 
dysplasia’s and Genetic Short Stature” as searching 
terms. All the articles found were filtered by 
language, selecting English and Spanish articles with 
more than 20 references and those from the last 6 
years (the majority), and some others older were 
took into account because they represented an 
important source. We chose review articles, original 
articles and case reports. Also review books were 
taken into account. We didn’t include meta-analysis 
and clinical trials. 
dIscussIon 
When we see a patient who complains of short 
stature, a series of questions and measures need to 
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be taken in order to classify the child and determine 
the diagnosis. Generally, we have two great causes 
of physiological short stature, GST and CDG. After 
taking measurements and solve the questions we 
should be able to classify short stature as pathological 
or physiological, and this last is sub classified in GST 
or CDG12, 13.
The first question to be inquired is whether in fact 
the child is stunted or is it just a subjective perception 
of parents, for this height and age are measured 
and placed on local height/age tables which is the 
ideal option; if they are no available WHO ones may 
be used in infants under five years and over this 
age CDC tables would be employed14,15. If values 
match properly, the kid must remain in growth and 
development control and not being studied for short 
stature, except if we can determine Height Velocity 
(HV) below two standard deviations away from the 
expected for age.
Once the stunting is confirmed, we must determine 
if it is proportionate or disproportionate. This 
can be done by measuring and comparing body 
segments. A useful measure is the wingspan, 
this is measured with open arms and starts from 
the third finger of one hand to the opposite one, 
this magnitude has to coincide with height. Apart 
from this, different segments dimensions have 
to be taken; in upper limb to discard pathologies 
relate to shortening like in rhizomelia (proximal 
segment), mezomelia (medial segment) or 
micromelia (distal segment). The inferior segment 
is measured by taking the distance from the pubic 
symphysis to the heels, and the superior segment 
is the result from rest the inferior segment to the 
height16,17 (See Picture 1). If after obtaining these 
measurements it is determined that the child 
has a disproportionate short stature he should 
be referred to a specialist, whether a geneticist, 
endocrinologist or orthopedist.
Observe and consider classic phenotypes of some 
diseases would be helpful, such as Turner syndrome 
(short stature women, with retarded puberty or no 
menarche, irregular cycles without developing of 
secondary sexual characteristics18,19), Silver Russell 
syndrome (Short stature, asymmetrical and long 
face, clinodactyly and asymmetrical limbs20-1), 
also check the implantation of ears and measure 
intercantal distance. 
If the child has a proportionate short stature it may 
suggest that we are facing an organic disease or a 
physiological short stature (GST or CDG)15. In order 
to classify the patient into any of these groups, HV 
must be obtained and placed in the most popular 
tables from longitudinal growth studies published by 
Tanner et al. and Prader et al.20-1. A HV, is traditionally 
determined at annual or semi-annual intervals, ergo 
the number of centimeters gained in the last year 
(cm/year). The measures should be taken in more 
than two or three times in order to build a HV. If the 
HV was in a normal percentile but at some point of 
time is altered and continues later on within this 
percentile, can lead us to think in organic disease or 
an endocrine problem that is starting at that moment, 
and in this case is important to have measurements 
before the beginning of the disease.
The Body Mass Index (BMI) provides useful 
information and allows us to differentiate between an 
endocrine or organic disease. At a higher BMI is more 
possible an endocrine disease, because most of the 
times they increase the body fat and interrupt normal 
growth. In contrast, BMI is lower than the appropriate 
for the stature when an organic disease is presented, 
Picture 1: Body’s segments measures
X1= wingspan. X2= Child’s height. X1 must be the same length 
as X2. 
Is= from the pubis symphysis to the heels. 
Ss=X2-Is.
Ps= Proximal segment, Ms= Medial segment, Ds= Distal segment.
Source: Authors.
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because it causes a loss of body fat in majority of the 
cases12,20. The principal organic and endocrine diseases 
that caused short stature are listed in Table 121-2.
not been well fed so they can give a high vitamin 
supplements diet or more food increasing obesity 
risk12,29,30.
Table 1. Principal organic and endocrine diseases that cause short 
stature
Organic disease Endocrine disease
Malnutrition, anemia Hypoparathyroidism
Infections: HIV, primary 
immunodeficiency’s
Hypopituitarism
Pulmonary: Asthma, 
interstitial neuropathies
Hypothyroidism
Cardiac: Congenic hearth 
disease 
Growth hormone primary 
deficiency
Gastrointestinal: Intestinal 
parasites, Cronh disease, 
malabsorption syndrome
Syndromes: Silver Russell, 
Turner, Down.
Renal: Chronic renal 
insufficiency
Bone dysplasia 
Small for Gestational Age 
(SGA)
Source: Authors23-7
Table 2. Principal differences between CDG and GST
CHARACTERISTICS CDG GST
Family stature Normal Decreased
History of delayed 
puberty in the family
Positive Negative
Location below -2 SD Around 2 or 3 
years
< First year
Dentition Delayed Normal
Risk during 
childhood and 
adolescence
Bullying and 
discrimination
Bullying, 
discrimination 
and obesity
Growth velocity peak 
on puberty
Normal or 
increased
Normal or 
decreased
Puberty Retarded Normal
Bone age Below the 
normal
Normal
IGF-1 Normal Between -1,-2 
SD
Final stature Normal Decreased
Source: Authors.
On the other scenario if the patient has presented 
a steady growth speed but still below the normal 
measures, we should think and evaluate a CDG or 
GST, which embrace the 80%10,11 of children with short 
stature. It’s important to differentiate between these 
two groups (See table 2), because the final reached 
stature will vary, and they have different risks during 
childhood12,14,28-9.
The first important difference is the genetic family 
stature, it can be taken measuring both parents high 
and averaging it and adding 6.5cm in males or resting 
6.5cm in females, that will be the final genetic stature 
expected for the child. In CDG final stature will be 
normal (above -2SD) and in GST will be decreased 
(below -2SD)14. Another important parameter is 
bone age, from a radiograph of the left hand and 
wrist, which is a measure of skeletal maturation 
and comparable to real age. This is most commonly 
determined by the Greulich-Pyle method and it is 
useful to predict a child’s height potential1,10,11.
It has been said before, the risks of these two groups 
are different, children with CDG would experience 
delayed puberty so they may feel themselves 
different and are more exposed to deal with bullying 
and discrimination. This is a common thing with GST, 
but in this case puberty is not retarded. The main 
difference in these characteristics is that the family 
of the children with GST may think the infant has 
The onset of the puberty has an important role in 
the final stature because when it begins before the 
normal age, under ten and nine years for boys and girls 
respectively, the HV peak will have a lower duration 
and the bone age will be affected, that traduces in 
a final stature decreased. Looking for initial signs of 
early puberty is very important in these patients, for 
example, female children with Tanner classification 
over two or three and with less than eight years, we 
must think on early puberty and make the reference 
to an endocrinologist31-2.
When patients with CDG finally reach the puberty, 
the growth velocity peak will be increased or may be 
normal, in contrast, those with GST will have a lower 
velocity peak in puberty31. If we take an x-ray of wrist 
and hands, those with CDG will have a decreased 
bone age so they can keep growing for an older age 
and finally reach a normal stature. That is different 
from GST, because infants will have a normal bone 
age, so they will grow until the normal age (15 for 
girls, 18 for boys)14,20,31.
One point to remember is that delayed puberty 
familiar history is only presented in CDG and the child 
would be located on -2SD at age of two or three, 
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different from GST where the infant is located in -2SD 
earlier (at first year or before)31. Also dentition will be 
delayed in CDG but not in GST. 
Another difference between CDG and GST is IGF-1 
level, because in CDG is in the normal range but in GST 
they could be in -1 or -2 SD; findings which confirm 
the important function of IGF-1 in all growth process, 
altogether with de Growth Hormone (GH)3,4,6,29,33-5. GH 
is mainly released at night and in a pulsatile manner; 
that’s why a basal value it is not useful; few cases 
need testing of GH and it is request by pediatric 
endocrinologist if needed but IGF1 should be suitable 
in primary care9,10,36.
It is very important that the primary care provider 
understands the physiological variations of growth 
stunting and knows how to differentiate it from 
pathological short stature, the first one can be 
managed and monitored in their level of attention, 
but pathological must be referred to a specialist in 
the field. In this review we aimed to provide a new 
perspective for this problem based on a good clinical 
history for patients with short stature, the measures 
and tests required to be taken and finally the manage 
of the disorder (See Figure 1).
Figure 1. Flowchart of management of short stature in first level
Source: Authors.
conclusIón
Short stature is a frequent query in primary care, so 
it is essential to differentiate physiological variants 
from pathological, to avoid referring children to 
pediatrician or an endocrinologist unnecessarily. 
There are different variants of physiological short 
stature that have special features that are important 
to know and being explained to parents, as they can 
create false expectations about the final height their 
children will have. To differentiate physiological from 
pathological short stature, primary care provider 
have to know what measures should be taken, to 
determinate if is a proportionate or disproportionate, 
and also is essential to understand the meaning of 
Body Mass Index and Growth Velocity in stunted 
children. In all this context of pathological short 
stature, there are a few phenotype characteristics 
that can guide the diagnosis to a genetic problem. 
Finally, the primary care provider has to understand 
the meaning of the different test with growth 
hormone and when a patient needs one. 
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